Stock Ratings / Health Care / IRMD / options

SGP (41) AORT (54) PRCT (48) SIBN (48) ⌘ Pro Terminal →

iRadimed Corporation (IRMD) Options Positioning, Max Pain & Unusual Sweeps

Q: Is IRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, iRadimed Corporation (NASDAQ: IRMD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $85.74 (+2.16% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IRMD ranks #110 in composite RQD confidence.

Q: How does IRMD compare to SGP and AORT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable C+ (68/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, SGP (SpyGlass Pharma Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.09B) and AORT (Artivion Inc.) posts a D+ grade (54/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for IRMD?

Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is IRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRMD last traded at $85.74 (+2.16% on volume of 92,640 shares), positioning the stock +0.09% above its 50-day simple moving average ($85.66) and -7.35% below its 200-day simple moving average ($92.54). Across its 52-week range of $76.35 to $107.90, IRMD sits at the 29.8% percentile with a 14-day RSI of 25.6 (OVERSOLD (<32)) and an implied next-earnings move of ±5.6% ($80.94 to $90.54).

Q: What is IRMD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for IRMD.

$85.74 +2.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $85.91

iRadimed Corporation (IRMD) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $1.10B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $85.91 (+0.20%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 20.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRMD)Realized 20D OHLCV Swing Band: ±5.6%

Deterministic 5-Pillar Attribution (68/100 Composite)

🔍 WHY IRMD SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 20.5% FCF Margin ($17.2M FCF) & 76.7% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (22% of score)

FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 25.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$87.45+0.9% Next Q

Q2 (-2Q)

Grade B$88.27-2.8% Next Q

Q3 (-1Q)

Grade B$85.82-0.1% Next Q

Current

Grade C+$85.74+1.8% Hist 90D α

Trajectory: B+ (76) → C+ (68)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IRMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, IRMD faces multiple-compression risk if 48.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.32% YoY Shares) — any gross margin slip below 74.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($85.66) or 200D SMA ($92.54) invalidates the momentum regime and cuts Target Base ($89.60) toward Bear Floor ($69.89).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 68%NO 32%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±5.6%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (IRMD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for IRMD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating IRMD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on IRMD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.76%📐 HORIZONTAL RANGE

2026-10-30O $82.28H $85.74L $76.35C $85.74VOL 218.0K

RES: $91.64SUP: $76.25SMA50: $85.66SMA200: $92.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRMD Butterfly Map → + Track IRMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

35.7%/yr Implied 5Y Growth

vs. +14.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRMD)

Health Care Rank #110 of 1016 ⚔️ SGP vs IRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRMD vs. SGP, AORT, PRCT, SIBN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, iRadimed Corporation (IRMD) ranks #110 by composite RQD confidence (68/100, grade C+) and #351 by equity capitalization ($1.10B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IRMD ACTIVE iRadimed Corporation	C+	68/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	Benchmark Subject
SGP SpyGlass Pharma Inc.	D-	41/100	—	—	-35.0%	-1.06%	$1.09B	/sgp-vs-irmd →
AORT Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-irmd →
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-irmd →
SIBN SI-BONE Inc.	D	48/100	—	79.6%	-10.3%	+2.66%	$1.00B	/sibn-vs-irmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001325618

In its most recent audited fiscal period (FY2025, filed 2025-12-31), iRadimed Corporation (IRMD) reported GAAP revenue of $83.8M (+14.4% vs. FY2024 revenue of $73.2M , and +27.8% cumulative change since FY2023) , GAAP net income of $22.5M, operating cash flow of $24.9M, and free cash flow of $17.2M (-2.5% YoY). On the balance sheet, IRMD closed FY2025 with $108.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$83.8M	$22.5M	$24.9M	$17.2M	$108.8M	—
FY2024 (FY)	2024-12-31	$73.2M	$19.2M	$25.6M	$17.6M	$98.3M	—
FY2023 (FY)	2023-12-31	$65.6M	$17.2M	$13.5M	$13.5M	—	—

3. IRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, iRadimed Corporation (NASDAQ: IRMD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $85.74 (+2.16% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IRMD ranks #110 in composite RQD confidence.

How does IRMD compare to SGP and AORT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable C+ (68/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, SGP (SpyGlass Pharma Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.09B) and AORT (Artivion Inc.) posts a D+ grade (54/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRMD?

Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRMD last traded at $85.74 (+2.16% on volume of 92,640 shares), positioning the stock +0.09% above its 50-day simple moving average ($85.66) and -7.35% below its 200-day simple moving average ($92.54). Across its 52-week range of $76.35 to $107.90, IRMD sits at the 29.8% percentile with a 14-day RSI of 25.6 (OVERSOLD (<32)) and an implied next-earnings move of ±5.6% ($80.94 to $90.54).

IRMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IRMD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for IRMD.

Direct Sub-Reports: IRMD RQD Cockpit IRMD 12M Forecast IRMD Earnings & Move IRMD Dividends & DRIP IRMD Insiders & 13F IRMD Whale Options IRMD Profit Sankey IRMD News & Why